Immix Biopharma Valuation
| IMMX Stock | USD 1.72 0.04 2.27% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Immix Biopharma retains a regular Real Value of $3.01 per share. The prevalent price of the firm is $1.72. Our model calculates the value of Immix Biopharma from evaluating the firm fundamentals such as Return On Asset of -0.61, return on equity of -1.18, and Shares Owned By Insiders of 40.09 % as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Immix Biopharma's valuation include:
Undervalued
Today
Please note that Immix Biopharma's price fluctuation is very risky at this time. Calculation of the real value of Immix Biopharma is based on 3 months time horizon. Increasing Immix Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Immix Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immix Stock. However, Immix Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.72 | Real 3.01 | Target 7.0 | Hype 1.72 | Naive 1.71 |
The intrinsic value of Immix Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immix Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immix Biopharma helps investors to forecast how Immix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immix Biopharma more accurately as focusing exclusively on Immix Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Immix Biopharma's intrinsic value based on its ongoing forecasts of Immix Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Immix Biopharma's closest peers.
Immix Biopharma Cash |
|
Immix Valuation Trend
Analysing the historical paterns of Immix Biopharma's enterprise value and its market capitalization is a good way to estimate and gauge the value of Immix Biopharma over time and is usually enough for investors to make rational market timing decisions.
Immix Biopharma Total Value Analysis
Immix Biopharma is currently expected to have valuation of 28.71 M with market capitalization of 44.84 M, debt of 3.72 M, and cash on hands of 18.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Immix Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
28.71 M | 44.84 M | 3.72 M | 18.4 M |
Immix Biopharma Asset Utilization
One of the ways to look at asset utilization of Immix is to check how much profit was generated for every dollar of assets it reports. Immix Biopharma retains a negative application of resources of -0.61 (percent), losing $0.006055 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Immix Biopharma shows how discouraging it operates for each dollar spent on its resources.Immix Biopharma Ownership Allocation
Immix Biopharma has a total of 27.51 Million outstanding shares. Immix Biopharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Immix Biopharma Profitability Analysis
Net Loss for the year was (15.6 M) with profit before overhead, payroll, taxes, and interest of 0.About Immix Biopharma Valuation
Our relative valuation model uses a comparative analysis of Immix Biopharma. We calculate exposure to Immix Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immix Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.9 K | -5.2 K | |
| Pretax Profit Margin | 0.08 | 0.07 | |
| Operating Profit Margin | 0.08 | 0.07 | |
| Net Profit Margin | 0.08 | 0.07 | |
| Gross Profit Margin | 0.90 | 0.80 |
Immix Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 17.3 M |
Immix Biopharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Immix Biopharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Immix we look at many different elements of the entity such as Immix's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Immix Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Immix Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Immix Biopharma's worth.Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.